Polypharmacy Guidance: appropriate prescribing, making medicines safe, effective and sustainable 2026 - 2029

26. References

1 Pearson-Stuttard, Jonathan et al., Multimorbidity—a defining challenge for health systems, The Lancet Public Health, Volume 4, Issue 12, e599 - e600, December 2019

2 Mair A., Fernandez-Limos F., Alonso A., Harrison C., Hurding S., et al. Polypharmacy Management by 2030: a patient safety challenge, 2nd Edition. Coimbra: SIMPATHY Consortium, 2017. (last accessed 6 January 2026)

3 Barnett K., Mercer S.W., Norbury M, Watt G., Wyke S., Guthrie B., Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet. 2012;380(9836):37-43

4 Mair A, Alonso, A., International Organisation of Integrated Care. Polypharmacy and Integrated care. Handbook of integrated care. Second edition. 2020. Springer. 978-3-030-69261-2 DOI :10.1007/978-3-030-69262-9_27

5 World Health Organization, Medication Without Harm - Global Patient Safety Challenge on Medication Safety. Geneva: 2017. Licence: CC BY-NC-SA 3.0 IGO

6 Mair, A., 2019. Medication safety in polypharmacy: technical report. (last accessed 6 January 2026)

7 World Health Organization, Medication Safety in High-risk Situations. Geneva; 2019 (WHO/UHC/SDS/2019.10). Licence: CC BY-NC-SA 3.0 IGO

8 World Health Organization, Global burden of preventable medication-related harm in health care: a systematic review. Geneva; 2023. Licence: CC BY-NC-SA 3.0 IGO

9 Mair A., Kirke C., Scott M. et al, iSIMPATHY: a multinational pre–post non-randomised intervention study transforming medication review. BMJ Open 2025;15:e102020. doi: 10.1136/bmjopen-2025-102020. (last accessed 6 January 2026)

10 Osanlou R. et al. Adverse drug reactions, multimorbidity and polypharmacy: A prospective analysis of one month of medical admissions. BMJ Open, 2022; 12(7), [e055551]. (last accessed 6 January 2026)

11 Kongkaew C et al. Risk factors for hospital admissions associated with adverse drug events. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy, 2013; 33(8):827–37. (last accessed 6 January 2026)

12 World Health Organization. Quality of care: a process for making strategic choices in health systems. Geneva; 2006

13 Royal College of Physicians, Acute care toolkit 17: Managing multiple medications, November 2024. (last accessed 6 January 2026)

14 Köberlein J. and Jürges H., Multimorbidity, incentives and the use of health services in Europe. In Active Ageing and Solidarity Between Generations in Europe: First Results from SHARE After the Economic Crisis, ed. A Börsch-Supan, M Brandt, H Litwin, G Weber, pp. 243–52. Berlin: de Gruyter, 2013

15 Guthrie B et al. Adapting clinical guidelines to take account of multimorbidity. BMJ 2012; 345:e6341. (last accessed 6 January 2026)

16 Shippee N.D. et al. Cumulative complexity: a functional, patient-centered model of patient complexity can improve research and practice. Journal of Clinical Epidemiology, 2012;.65(10):1041–51. (last accessed 6 January 2026)

17 Lu CY., Roughead E., Determinants of patient-reported medication errors: a comparison among seven countries. Int J Clin Pract, 2011, 65 (7):733-740, 2011. doi:10.1111/j.1742-1241.02671.x

18 Mannucci P.M., Nobili A., Pasina L., Collaborators R., Polypharmacy in older people: lessons from 10 years of experience with the REPOSI register. Intern Emerg Med, 2018, 13 (8):1191-1200. doi:10.1007/s11739-018-1941-8

19 Cullinan S., Raae Hansen C., Byrne S., et al., Challenges of deprescribing in the multimorbid patient. Eur J Hosp Pharm, 2017, 24 (1):43-46. doi:10.1136/ejhpharm-2016-000921

20 Frank C, Weir E, Deprescribing for older patients. CMAJ, 2014, 186 (18):1369-1376. doi:10.1503/cmaj.131873

21 Latimer S., Hewitt J., Teasdale T. et al., The accuracy, completeness and timeliness of discharge medication information and implementing medication reconciliation: A cross-sectional survey of general practitioners. Aust J Gen Pract, 2020; 49 (12):854-858. doi:10.31128/AJGP-04-20-5375

22 Rochon P.A., Gurwitz J.H., The prescribing cascade revisited. Lancet, 2017, 389 (10081):1778-1780. doi:10.1016/S0140-6736(17)31188-1

23 Cohen M.R., Medication errors. 2nd ed. Washington, DC: American Pharmacist Association; 2007

24 Australian Commission on Safety and Quality in Healthcare website, APINCHS classification of high-risk medicines. (last accessed 6 January 2026)

25 Scottish Government Polypharmacy Model of Care Group. Polypharmacy guidance, realistic prescribing. 3rd ed. Scottish Government; 2018. (last accessed 6 January 2026)

26 Mair A., Wilson M., Dreischulte T., Addressing the challenge of polypharmacy. Annu Rev Pharmacology Toxicol. 2020;60(1):661–81. (last accessed 6 January 2026)

27 Qaseem A, Wilt T.J., Kansagara D. et al., Clinical Guidelines Committee of the American College of Physicians, Fitterman N, Balzer K, Boyd C, Humphrey L.L., Iorio A, Lin J, Maroto M, McLean R, Mustafa R, Tufte J. Hemoglobin A1c targets for glycemic control with pharmacologic therapy for nonpregnant adults with type 2 diabetes mellitus: a guidance statement update from the American College of Physicians. Ann Intern Med. 2018;168(8):569–76. (last accessed 6 January 2026)

28 Medicines and Healthcare products Regulatory Agency, Outcome of MHRA review of neuropsychiatric reactions with montelukast, (April 2024). (last accessed 6 January 2026)

29 Pirmohamed M., James S., Meakin S. et al., Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ. 2004;329(7456):15–9. (last accessed 6 January 2026)

30 Scottish Government, Quality prescribing for Benzodiazepines and z-drugs: guide for improvement 2024 to 2027, 2024. (last accessed 6 January 2026)

31 Maust D.T., Kim H.M., Seyfried L.S., et al., Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm. JAMA Psychiatry. 2015;72(5):438–45. (last accessed 6 January 2026)

32 Banerjee S. The use of antipsychotic medication for people with dementia: time for action, 2009. (last accessed 6 January 2026)

33 Komagamine J, Kobayashi M. Prevalence of hospitalisation caused by adverse drug reactions at an internal medicine ward of a single Centre in Japan: a cross-sectional study. BMJ Open. 2019;9(8):e030515. (last accessed 6 January 2026)

34 Agrawal M, Singh P, Joshi U. Antimicrobials associated adverse drug reaction profiling: a four years retrospective study (Pharmacovigilance study). Alexandria J Med. 2021;57(1):177–87. (last accessed 6 January 2026)

35 Hodkinson et al., Preventable medication harm across health care settings: a systematic review and meta-analysis. BMC Medicine, 2020; 18:313.

36 Schwendimann R, et al., The occurrence, types, consequences and preventability of in-hospital adverse events – a scoping review. BMC Health Services Research, 2018; 18:521

37 Auraaen A, et al., The economics of patient safety in primary and ambulatory care: Flying blind. OECD Health Working Papers, 2018; No. 106, OECD Publishing, Paris

38 Moore M.H., Creating Public Value - Strategic Management in Government. Cambridge, MA: Harvard University Press, 1997. ISBN: 9780674175587

39 Martyn-St James et. al., Evidence for the impact of interventions and medicines reconciliation on problematic polypharmacy in the UK: A rapid review of systematic reviews. Br J Clin Pharmacol. 2021 Jan;87(1):42-75. doi: 10.1111/bcp.14368. Epub 2020 Jul 5. PMID: 32424902

40 Page A.T., Clifford R.M., Potter K., et al., The feasibility and effect of deprescribing in older adults on mortality and health: a systematic review and meta-analysis. Br J Clin Pharmacol. 2016 Sep;82(3):583-623. doi: 10.1111/bcp.12975. Epub 2016 Jun 13. PMID: 27077231; PMCID: PMC5338123

41 Avery, A. et al., A pharmacist-led information technology intervention for medication errors (PINCER): a multicentre, cluster randomised, controlled trial and cost-effectiveness analysis. Lancet 2012; 379: 1310–19

42 Dreischulte T. et al., Safer Prescribing: A Trial of Education, Informatics, and Financial Incentives. New England Journal of Medicine, 2016; 374(11), 1053-1064

43 Swinglehurst, D., Hogger, L. and Fudge, N., Negotiating the polypharmacy paradox: a video-reflexive ethnography study of polypharmacy and its practices in primary care. BMJ Quality & Safety, 2023, 32(3), pp.150-159.

44 NHS Scotland. National Therapeutic Indicators 2018. NHS Scotland: Edinburgh; 2018

45 Okeowo D.A., Zaidi S.T.R., Fylan B., Alldred D.P., Barriers and facilitators of implementing proactive deprescribing within primary care: a systematic review. Int J Pharm Pract. 2023 Apr 10;31(2):126-152. doi: 10.1093/ijpp/riad001. PMID: 36860190

46 Peat G., Fylan B., Marques I., et al. Barriers and facilitators of successful deprescribing as described by older patients living with frailty, their informal carers and clinicians: a qualitative interview study. BMJ Open 2022;12:e054279. doi:10.1136/ bmjopen-2021-054279. (last accessed 6 January 2026)

47 Laupacis A., Sackett D., Roberts R., An Assessment of Clinically Useful Measures of the Consequences of Treatment. New England Journal of Medicine. 1988;318(26):1728-1733

48 Cook R., Sackett D., The number needed to treat: a clinically useful measure of treatment effect. BMJ. 1995;310(6977):452-454

49 McAlister, F.A., The “number needed to treat” turns 20—and continues to be used and misused. Cmaj, 2008; 179(6), pp.549-553

50 Guthrie B., Thompson A., Dumbreck S., et al., Better guidelines for better care: accounting for multimorbidity in clinical guidelines – structured examination of exemplar guidelines and health economic modelling. Health Services Delivery Research 2017;5(16)

51 Canadian Medication Appropriateness and Deprescribing Network (CaDen) website. What is deprescribing? Bruyère Research Institute; 2021. (last accessed 6 January 2026)

52 Lyles L.F., Hildebrandt H, Mair A., Population health management approach: integration of community-based pharmacists into integrated care systems: reflections from the U.S., achievements in Scotland and discussions in Germany. Int J Integr Care. 2020;20(2):13. (last accessed 6 January 2026)

53 Mair A., Antoniadou E., Hendry A., Gabrovec B., Appropriate polypharmacy: a barometer for integrated care. J Integr Care. 2020;29:204

54 Leelakanok N., Holcombe A.L., Lund B.C., et al., Association between polypharmacy and death: A systematic review and meta-analysis. J Am Pharm Assoc (2003). 2017 Nov-Dec;57(6):729-738.e10. doi: 10.1016/j.japh.2017.06.002. Epub 2017 Aug 5. PMID: 28784299

55 Abbott R.A., Moore D.A., Rogers M., et al., Effectiveness of pharmacist home visits for individuals at risk of medication-related problems: a systematic review and meta-analysis of randomised controlled trials. BMC health services research. 2020 Dec;20(1):1-5

56 Sempé L., Billings J., Lloyd-Sherlock P., Multidisciplinary interventions for reducing the avoidable displacement from home of frail older people: a systematic review. BMJ open. 2019 Nov 1;9(11):e030687

57 Walters K., Frost R., Kharicha K., et al., Home-based health promotion for older people with mild frailty: the HomeHealth intervention development and feasibility RCT. Health Technology Assessment (Winchester, England). 2017 Dec;21(73):1

58 Ahmed A., van den Muijsenbergh M.E., Mewes J.C., et al., Untangling the inter-relatedness within integrated care programmes for community-dwelling frail older people: a rapid realist review. BMJ open. 2021 Apr 1;11(4):e043280

59 Pazan, F. and Wehling, M., Polypharmacy in older adults: a narrative review of definitions, epidemiology and consequences. European Geriatric Medicine, 2021; 12, pp.443-452. (last accessed 6 January 2026)

60 Faulkner, L., Hughes, C., and Barry, H., A systematic review of interventions to improve medicines optimisation in frail older people in primary care. International Journal of Pharmacy Practice, 2020; 28(S1), p.48. (last accessed 6 January 2026)

61 Gabrovec, B., Antoniadou, E., Soleymani, D., et al., Need for comprehensive management of frailty at an individual level: European perspective from the advantage joint action on frailty. Journal of Rehabilitation Medicine, 2020; 52(6), p.jrm00075. (last accessed 6 January 2026)

62 Ibrahim, K., Cox, N.J., Stevenson, J.M., et al., A systematic review of the evidence for deprescribing interventions among older people living with frailty. BMC geriatrics, 2021; 21, pp.1-16. (last accessed 6 January 2026)

63 Rankin, A., Cadogan, C.A., Patterson, S.M., et al., Interventions to improve the appropriate use of polypharmacy for older people. Cochrane Database of Systematic Reviews, 2018. (9). (last accessed 6 January 2026)

64 Thompson, W., Lundby, C., Graabæk, T., et al., Tools for deprescribing in frail older persons and those with limited life expectancy: a systematic review. Journal of the American Geriatrics Society, 2019; 67(1), pp.172-180. (last accessed 6 January 2026)

65 BC Guidelines. Frailty in Older Adults–Early Identification and Management. 2017. (last accessed 6 January 2026)

66 BMA Identification and management of patients with frailty. 2020

67 Specialist Pharmacy Service, ‘Cardiovascular disease in older people living with frailty: Optimising medicines in multimorbidity and polypharmacy’, 2020.

68 Liau S., Lalic S., Sluggett J., et al. Optimizing Geriatric Pharmacotherapy through Pharmacoepidemiology Network (OPPEN) Medication management in frail older people: consensus principles for clinical practice, research and education. J Am Med Dir Assoc. 2020;22(1):43-9

69 Royal Australian College of General Practitioners, Part, A., Royal Australian College of General Practitioners, Aged Care Clinical Guide (Silver Book) (last accessed 6 January 2026)

70 British Geriatrics Society. Ambitions for change: improving healthcare in care homes, 2021. (last accessed 6 January 2026)

71 I-Hub. Living well in Communities with Frailty Evidence for what works. 2018

72 NHS England and NHS Improvement. The Framework for Enhanced Health in Care Homes Version 2. 2020

73 Almutairi H., Stafford A., Etherton-Beer C., Flicker L., Optimisation of medications used in residential aged care facilities: a systematic review and meta-analysis of randomised controlled trials. BMC geriatrics. 2020 Dec;20(1):1-9

74 Clyne B., Fitzgerald C., Quinlan A. et al., Interventions to address potentially inappropriate prescribing in community‐dwelling older adults: a systematic review of randomized controlled trials. Journal of the American Geriatrics Society. 2016 Jun;64(6):1210-22

75 Hill‐Taylor, B., Walsh, K.A., Stewart, S., et al., Effectiveness of the STOPP/START (Screening Tool of Older Persons' potentially inappropriate Prescriptions/Screening Tool to Alert doctors to the Right Treatment) criteria: systematic review and meta‐analysis of randomized controlled studies. Journal of clinical pharmacy and therapeutics, 2016; 41(2), pp.158-169

76 Johansson T., Abuzahra M.E., Keller S. et al., Impact of strategies to reduce polypharmacy on clinically relevant endpoints: a systematic review and meta‐analysis. British journal of clinical pharmacology. 2016 Aug;82(2):532-48

77 Kua C.H., Mak V.S., Lee S.W., Health outcomes of deprescribing interventions among older residents in nursing homes: a systematic review and meta-analysis. Journal of the American Medical Directors Association. 2019 Mar 1;20(3):362-72

78 Stewart D., Gibson-Smith K., MacLure K., Mair A., et al., A modified Delphi study to determine the level of consensus across the European Union on the structures, processes and desired outcomes of the management of polypharmacy in older people. PLoS One, 2017; 12 (11):e0188348. doi:10.1371/journal.pone.0188348

79 McIntosh J., Alonso A., MacLure K., et al., A case study of polypharmacy management in nine European countries: Implications for change management and implementation. PLoS One, 2018; 13 (4):e0195232. doi:10.1371/journal.pone.0195232

80 Stewart D., Mair A., Wilson M., et al., Guidance to manage inappropriate polypharmacy in older people: systematic review and future developments. Expert Opin Drug Saf, 2017; 16 (2):203-213. doi:10.1080/14740338.2017.1265503

81 Etxeberria A., Iribar J., Vrotsou K., et al., Evaluation of the collaboration between primary and hospital care in order to improve inappropriate prescription. Journal of Healthcare Quality Research, 2021;36(2):91–7. (last accessed 6 January 2026)

82 Hanlon J.T. et al. A method for determining drug therapy appropriateness. Journal of Clinical Epidemiology, 1992; 45 (10): 1045. (last accessed 6 January 2026)

83 Burt J., Elmore N., Campbell S.M., et al., Developing a measure of polypharmacy appropriateness in primary care: systematic review and expert consensus study. BMC Med 16 (1):91., 2018. doi:10.1186/s12916-018-1078-7

84 A. Seppala, L.J., Petrovic, M., Ryg, J., et al., STOPPFall (screening tool of older persons prescriptions in older adults with high fall risk): a Delphi study by the EuGMS task and finish group on fall-risk-increasing drugs. Age and ageing, 2021; 50(4), pp.1189-1199. (last accessed 6 January 2026)

85 Lee, J., Negm, A., Peters, R., et al., Deprescribing fall-risk increasing drugs (FRIDs) for the prevention of falls and fall-related complications: a systematic review and meta-analysis. BMJ open, 2021; 11(2), p.e035978. (last accessed 6 January 2026)

86 National Falls Prevention Coordination Group (NFPCG) 2023. Medicines and Falls. (last accessed 6 January 2026)

87 ACB Calculator website, created by Dr Rebecca King & Steve Rabino. (last accessed 6 January 2026)

88 The Senior List, List of Anticholinergic Drugs and Why Some of Them are Dangerous for Seniors, February 2024. (last accessed 6 January 2026)

89 Mair, A., Evidence of the Impact of Interventions to Decrease Polypharmacy. In Encyclopaedia of Evidence in Pharmaceutical Public Health and Health Services Research in Pharmacy, 2023; Springer Cham. (last accessed 6 January 2026)

90 de Bienassis, K., et al. The economics of medication safety: Improving medication safety through collective, real-time learning, OECD Health Working Papers, No. 147, OECD Publishing, Paris, 2022. (last accessed 6 January 2026)

91 European Directorate for the Quality of Medicines & HealthCare (EDQM), (2022) “Polypharmacy and ageing” – EDQM participation in ESCP symposium in Prague, (EDQM). (last accessed 6 January 2026)

92 Miall, N., Fergie, G., & Pearce, A., Health Inequalities in Scotland: trends in deaths, health and wellbeing, health behaviours, and health services since 2000. University of Glasgow, 2022. 10.36399/gla.pubs.282637

93 McCartney, G., Popham, F., McMaster, R., et al., Defining health and health inequalities. Public Health, 2019; 172, 22–30. 10.1016/j.puhe.2019.03.023

94 Rockwood K et al. A global clinical measure of fitness and frailty in elderly people. CMAJ 2005;173:489–495

95 New South Wales Government, Clinical Excellence Commission, Medication safety and quality: High-risk medications., 2024. (last accessed 6 January 2026)

96 Pirmohamed, M. Pharmacogenomics: current status and future perspectives. Nature Reviews Genetics, 2023; 24, 350–362. (last accessed 6 January 2026)

97 Davies E.A., O'Mahony M.S., Adverse drug reactions in special populations - the elderly. British Journal of Clinical Pharmacology, 2015;80(4):796–807

98 LeRoith, D., Biessels, G.J., Braithwaite, S.S. et al., Treatment of diabetes in older adults: an Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism, 2019; 104(5), pp.1520-1574. (last accessed 6 January 2026)

99 Sinclair, A.J., Dashora, U., George, S., Dhatariya, K. and JBDS‐IP Writing Group, Joint British Diabetes Societies for Inpatient Care (JBDS‐IP) Clinical Guideline Inpatient care of the frail older adult with diabetes: an executive summary. Diabetic Medicine, 2020; 37(12), pp.1981-1991. (last accessed 6 January 2026)

100 Williams, Mancia et al. European Society of Cardiology and European Society of Hypertension, Guidelines for the Management of Arterial Hypertension, 2018. J Hypertens 2018;36:1953-2041 and Eur Heart J 2018;39:3021-3104

101 National Institute of Health and Care Excellence guideline, Hypertension in adults: diagnosis and management, NG136, 2019. (last accessed 6 January 2026)

102 Hale M., Zaman H., Mehdizadeh D., et al., Association between statins prescribed for primary and secondary prevention and major adverse cardiac events among older adults with frailty: a systematic review. Drugs & Aging. 2020;37(11):787-99

103 Mallery, L., Moorhouse, P., McLean-Veysey, P., et al., Systematic review and meta-analysis of antidepressants for depression in frail older adults with and without dementia and the neuropsychiatric symptoms of dementia. Dalhousie University, Halifax, Canada, S, 2016; pp.1-102.

104 Seibert, M., Mühlbauer, V., Holbrook, J. et al. Efficacy and safety of pharmacotherapy for Alzheimer’s disease and for behavioural and psychological symptoms of dementia in older patients with moderate and severe functional impairments: a systematic review of controlled trials. Alzheimer’s Research & Therapy 2021; 13, 131. (last accessed 6 January 2026)

105 Scottish Government, Quality prescribing for antidepressants: guide for improvement 2024 to 2027, 2024. (last accessed 6 January 2026)

106 Parsons C., Lim W.Y., Loy C., et al. Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia. Cochrane Database of Systematic Reviews. 2021 Feb 3;2(2):CD009081. doi: 10.1002/14651858.CD009081.pub2. PMID: 35608903; PMCID: PMC8094886.

107 Maust D.T., Kim H.M., Seyfried L.S., et al., Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm. JAMA Psychiatry 2015; 72 (5):438-445. (last accessed 6 January 2026)

108 Taxonomy used in the World Falls Guidelines. Manuel Montero-Odasso and others, World guidelines for falls prevention and management for older adults: a global initiative, Age and Ageing, Volume 51, Issue 9, September 2022, afac205, (last accessed 6 January 2026)

109 Berry S.D., Miller R.R., Falls: epidemiology, pathophysiology, and relationship to fracture. Current Osteoporosis Reports. 2008 Dec;6(4):149-54. doi: 10.1007/s11914-008-0026-4. PMID: 19032925; PMCID: PMC2793090

110 Scottish Intercollegiate Guidelines Network, Management of osteoporosis and the prevention of fragility fractures, SIGN 142 (updated January 2021). (last accessed 6 January 2026)

111 Manias, E., Kabir, M.Z. and Maier, A.B., Inappropriate medications and physical function: a systematic review. Therapeutic Advances in Drug Safety, 2021; 12, p.20420986211030371. (last accessed 6 January 2026)

112 Mekonnen, A.B., Redley, B., de Courten, B. and Manias, E., Potentially inappropriate prescribing and its associations with health‐related and system‐related outcomes in hospitalised older adults: a systematic review and meta‐analysis. British Journal of Clinical Pharmacology, 2021; 87(11), pp.4150-4172. (last accessed 6 January 2026)

113 Mohamed, M.R., Ramsdale, E., Loh, K.P., et al., Associations of polypharmacy and inappropriate medications with adverse outcomes in older adults with cancer: a systematic review and meta‐analysis. The Oncologist, 2020; 25(1), pp.e94-e108. (last accessed 6 January 2026)

114 Seppala, L.J., van de Glind, E.M., Daams, J.G., et al., Fall-risk-increasing drugs: a systematic review and meta-analysis: III. Others. Journal of the American Medical Directors Association, 2018; 19(4), pp.372-e1. (last accessed 6 January 2026)

115 Cameron, I.D., Dyer, S.M., Panagoda, C.E., et al., Interventions for preventing falls in older people in care facilities and hospitals. Cochrane database of systematic reviews, 2018; (9). (last accessed 6 January 2026)

116 Hopewell, S., Adedire, O., Copsey, B.J., et al., Multifactorial and multiple component interventions for preventing falls in older people living in the community. Cochrane database of systematic reviews, 2018; (7). (last accessed 6 January 2026)

117 Public Health England, Falls and fracture consensus statement, Resource pack, 2017. (last accessed 6 January 2026)

118 Public Health England, A structured literature review to identify cost-effective interventions to prevent falls in older people living in the community, 2018. (last accessed 6 January 2026)

119 Registered Nurses’ Association of Ontario, Preventing falls and reducing injury from falls, 2017. (last accessed 6 January 2026)

120 Welsh Government, Principles, Framework and National Indicators: Adult In-Patient Falls, 2016. (last accessed 6 January 2026)

121 NICE. ‘2019 surveillance of falls in older people: assessing risk and prevention (NICE guideline CG161)’. 2019

122 NICE, 2013. ‘Falls in older people: assessing risk and prevention (CG161)’. Edited by excellence NIfHaC. 2013.

123 Nishtala P.S., Salahudeen M.S., Hilmer S.N., Anticholinergics: theoretical and clinical overview. Expert Opinion on Drug Safety 2016; 15 (6):753-768. doi:10.1517/14740338.2016.1165664

124 Risacher S.L., McDonald B.C., Tallman E.F., et al., Alzheimer's Disease Neuroimaging I., Association Between Anticholinergic Medication Use and Cognition, Brain Metabolism, and Brain Atrophy in Cognitively Normal Older Adults. JAMA Neurology 2016; 73 (6):721-732. doi:10.1001/jamaneurol.2016.0580

125 Duran C.E., Azermai M, Vander Stichele R.H., Systematic review of anticholinergic risk scales in older adults. European Journal of Clinical Pharmacology 2013; 69 (7):1485-1496.

126 Bishara D, Harwood D, Sauer J, Taylor D.M., Anticholinergic effect on cognition (AEC) of drugs commonly used in older people. International Journal of Geriatric Psychiatry 2017; 32 (6):650-656. doi:10.1002/gps.4507

127 Chew M.L., Mulsant B.H., Pollock B.G., et al., Anticholinergic activity of 107 medications commonly used by older adults. Journal of the American Geriatrics Society 2008; 56 (7):1333-1341

128 Sumukadas D, McMurdo M, Mangoni A, Guthrie B. Temporal trends in anticholinergic medication prescription in older people: repeated cross-sectional analysis of population prescribing data. Age and Ageing. 2013;43(4):515-521

129 Hilmer S.N., Gnjidic D. The anticholinergic burden: from research to practice. Australian Prescriber. 2022;45(4):118.

130 Rudolph J.L., Salow M.J., Angelini M.C., McGlinchey R.E., The anticholinergic risk scale and anticholinergic adverse effects in older persons. Archives of Internal Medicine, 2008;168:508e513.

131 Boustani M, Campbell N, Munger S, et al. Impact of anticholinergics on the aging brain: A review and practical application. Aging Health 2008;4:311‒ 320

132 Marcantonio E.R. Delirium in hospitalized older adults. New England Journal of Medicine 2017;377: 1456e1466.

133 National Institute for Health and Care Excellence. Dementia: assessment, management and support for people living with dementia and their carers [NG97], 2018. (last accessed 6 January 2026)

134 Modified Anticholinergic Risk Scale (mARS) Anticholinergic drugs (last accessed 6 January 2026)

135 Egberts A., Moreno-Gonzalez R., Alan H., et al., Anticholinergic drug burden and delirium: a systematic review. Journal of the American Medical Directors Association. 2021; Jan 1;22(1):65-73

136 Welsh T.J., van der Wardt V., Ojo G., et al., Anticholinergic drug burden tools/scales and adverse outcomes in different clinical settings: a systematic review of reviews. Drugs & Aging. 2018; Jun;35(6):523-38

137 Ali S, Peterson G.M., Bereznicki L.R., Salahudeen M.S., Association between anticholinergic drug burden and mortality in older people: a systematic review. European Journal of Clinical Pharmacology. 2020 Mar;76(3):319-35

138 NHS Business Service Authority. Medication Safety–Indicators Specification. NHS Business Services Authority (NHS BSA). 2019:2019-02

139 National Institute for Health and Care Excellence. Urinary incontinence and pelvic organ prolapse in women: management (NG123). 2019, London. (last accessed 6 January 2026)

140 Mehdizadeh D., Hale M., Todd O., et al., Associations Between Anticholinergic Medication Exposure and Adverse Health Outcomes in Older People with Frailty: A Systematic Review and Meta-analysis. Drugs-real world outcomes. 2021 Dec;8(4):431-58

141 Taylor-Rowan M., Edwards S., Noel-Storr A.H., et al., Anticholinergic burden (prognostic factor) for prediction of dementia or cognitive decline in older adults with no known cognitive syndrome. Cochrane Database of Systematic Reviews. 2021(5)

142 Stewart C., Taylor-Rowan M., Soiza R.L., et al., Anticholinergic burden measures and older people's falls risk: a systematic prognostic review. Therapeutic Advances in Drug Safety. 2021 May 31;12:20420986211016645. doi:10.1177/20420986211016645. PMID: 34104401; PMCID: PMC8170331

143 Reinold J., Schäfer W., Christianson L., et al., Anticholinergic burden and fractures: a systematic review with methodological appraisal. Drugs & Aging. 2020 Dec;37(12):885-97

144 Nakham A., Myint P.K., Bond C.M., et al., Interventions to reduce anticholinergic burden in adults aged 65 and older: a systematic review. Journal of the American Medical Directors Association. 2020 Feb 1;21(2):172-80

145 Ehrt U., Broich K., Larsen J., et al., Use of drugs with anticholinergic effect and impact on cognition in Parkinson's disease: a cohort study. Journal of Neurology, Neurosurgery & Psychiatry. 2009;81(2):160-165

146 Sittironnarit G., Ames D., Bush A., et al., Effects of Anticholinergic Drugs on Cognitive Function in Older Australians: Results from the AIBL Study. Dementia and Geriatric Cognitive Disorders. 2011;31(3):173-178

147 Huang W.C., Yang A.S., Tsai D.H., et al., Association between recently raised anticholinergic burden and risk of acute cardiovascular events: nationwide case-case-time-control study. BMJ. 2023 Sep 27;382:e076045. doi: 10.1136/bmj-2023-076045. PMID: 37758279; PMCID: PMC10523277. (last accessed 6 January 2026)

148 Royal Pharmaceutical Society, Pharmacy’s Role in Climate Action and Sustainable Healthcare. (last accessed 6 January 2026)

149 Department of Health and Social Care, Good for you, good for us, good for everybody A plan to reduce overprescribing to make patient care better and safer, support the NHS, and reduce carbon emissions, 2021. (last accessed 6 January 2026)

150 Trueman, P., Taylor, D.G., Lowson, K., et al., Evaluation of the scale, causes and costs of waste medicines. Report of DH funded national project. York Health Economics Consortium and The School of Pharmacy, University of London., 2010, York and London (last accessed 6 January 2026)

151 Giana Carli Lorenzini, Alison Bell, Annika Olsson, ‘You need to be healthy to be sick’: exploring older people’s experiences with medication packaging at home, Age and Ageing, Volume 51, Issue 3, March 2022, afac050. (last accessed 6 January 2026)

152 Tennison, Imogen et al. Health care's response to climate change: a carbon footprint assessment of the NHS in England, The Lancet Planetary Health, Volume 5, Issue 2, e84 - e92, February 2021. (last accessed 6 January 2026)

153 Raffaeli W., Tenti M., Corraro A., et al., Chronic Pain: What Does It Mean? A Review on the Use of the Term Chronic Pain in Clinical Practice. Journal of Pain Research. 2021 Mar 29;14:827-835. doi:10.2147/JPR.S303186. PMID: 33833560; PMCID: PMC8019660. (last accessed 6 January 2026)

154 NHS Inform website, Chronic pain. (last accessed 6 January 2026)

155 National Institute for Health and Clinical Excellence NG193, Chronic pain (primary and secondary) in over 16s: assessment of all chronic pain and management of chronic primary pain 2021. (last accessed 6 January 2026)

156 Derry, S., Bell, R.F., Straube, S., et al., Pregabalin for neuropathic pain in adults. Cochrane Database of Systematic Reviews, 2019 (1). (last accessed 6 January 2026)

157 Scottish Intercollegiate Guidelines Network (SIGN), Management of Chronic Pain SIGN 136, 2019. (last accessed 7 February 2025)

158 Scottish Palliative Care Guidelines Group, Scottish Palliative Care Guidelines, 2019. (last accessed 6 January 2026)

159 UK Government, Medicines and Healthcare Products Regulatory Agency, Drug Safety Update, 2020 Opioids: risk of dependence and addiction. (last accessed 6 January 2026)

160 Public Health England, Dependence and withdrawal associated with some prescribed medicines, 2019. London. (last accessed 6 January 2026)

161 Nury, E., Schmucker, C., Nagavci, B., et al., Efficacy and safety of strong opioids for chronic noncancer pain and chronic low back pain: a systematic review and meta-analyses. Pain, 2022;163(4), pp.610-636. (last accessed 6 January 2026)

162 Petzke, F., Klose, P., Welsch, P., et al., Opioids for chronic low back pain: An updated systematic review and meta‐analysis of efficacy, tolerability and safety in randomized placebo‐controlled studies of at least 4 weeks of double‐blind duration. European Journal of Pain, 2020; 24(3), pp.497-517. (last accessed 6 January 2026)

163 Korownyk, C.S., Montgomery, L., Young, J., et al., PEER simplified chronic pain guideline: Management of chronic low back, osteoarthritic, and neuropathic pain in primary care. Canadian Family Physician, 2022; 68(3), pp.179-190. (last accessed 6 January 2026)

164 Chou R., Hartung D., Turner J., et al., Opioid Treatments for Chronic Pain. Agency for Healthcare Research and Quality 2020:04.

165 Noori A., Sadeghirad B., Wang L., et al., Comparative benefits and harms of individual opioids for chronic non-cancer pain: a systematic review and network meta-analysis of randomised trials. British Journal of Anaesthesia 2022;129:394-406.

166 Chou R., Selph S., Wagner J., et al., Systematic Review on Opioid Treatments for Chronic Pain: Surveillance Report 1. Rockville, MD: Agency for Healthcare Research and Quality; 2022. (last accessed 6 January 2026)

167 Chou R, Selph S, Wagner J, Ahmed A.Y., Jungbauer R, Mauer K, et al. Systematic Review on Opioid Treatments for Chronic Pain: Surveillance Report 2. Rockville, MD: Agency for Healthcare Research and Quality; 2022. (last accessed 6 January 2026)

168 Chou R, Selph S, Wagner J, Ahmed AY, Jungbauer R, Mauer K, et al. Systematic Review on Opioid Treatments for Chronic Pain: Surveillance Report 3. Rockville, MD: Agency for Healthcare Research and Quality; 2022. (last accessed 6 January 2026)

169 Krebs E.E., Gravely A., Nugent S., et al., Effect of Opioid vs Nonopioid Medications on Pain-Related Function in Patients With Chronic Back Pain or Hip or Knee Osteoarthritis Pain: The SPACE Randomized Clinical Trial. JAMA 2018;319(9):872-82.

170 Scottish Intercollegiate Guidelines Network (SIGN), SIGN 173 Management of chronic pain (Part 1), December 2025. (last accessed 6 January 2026)

171 Dowell, D., Ragan, K.R., Jones, C.M., et al., Prescribing Opioids for Pain—The New CDC Clinical Practice Guideline. New England Journal of Medicine, 2022. (last accessed 6 January 2026)

172 Wong, G., Pharmacological management of chronic non-cancer pain in frail older people. Australian Prescriber, 2022; 45(1), p.2. (last accessed 6 January 2026)

173 Chou, R., Turner, J.A., Devine, E.B., et al., The effectiveness and risks of long-term opioid therapy for chronic pain: a systematic review for a National Institutes of Health Pathways to Prevention Workshop. Annals of Internal Medicine, 2015; 162(4), pp.276-286. (last accessed 6 January 2026)

174 Colvin, L.A. and Fallon, M.T., Opioid-induced hyperalgesia: a clinical challenge., British Journal of Anaesthesia, 2010; 104(2), pp.125-127. (last accessed 6 January 2026)

175 Daniell, H.W., Hypogonadism in men consuming sustained-action oral opioids. The Journal of Pain, 2002; 3(5), pp.377-384. (last accessed 6 January 2026)

176 Daniell, H.W., Opioid endocrinopathy in women consuming prescribed sustained-action opioids for control of nonmalignant pain. The Journal of Pain, 2008; 9(1), pp.28-36. (last accessed 6 January 2026)

177 Scottish Government, Quality Prescribing for Chronic Pain: A Guideline for Improvement 2017- 2020, 2018. (last accessed 6 January 2026)

178 Birkinshaw H., Friedrich C.M., Cole P., et al., Antidepressants for pain management in adults with chronic pain: a network meta-analysis. Cochrane Database of Systematic Reviews 2023;5:CD014682.

179 Welsch P., Üçeyler N., Klose P., et al., Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia. Cochrane Database of Systematic Reviews 2018(2).

180 Taylor, D.M., Barnes, T.R. and Young, A.H., The Maudsley prescribing guidelines in psychiatry, 2021. John Wiley & Sons.

181 UK Government, Medicines and Healthcare Products Regulatory Agency, Drug Safety Update 2017. Gabapentin (Neurontin): risk of severe respiratory depression. (last accessed 6 January 2026)

182 UK Government, Medicines and Healthcare Products Regulatory Agency, Drug Safety Update, 2021. Pregabalin (Lyrica): reports of severe respiratory depression. (last accessed 6 January 2026)

183 Jani M., Girard N., Bates D.W., et al., Comparative risk of mortality in new users of prescription opioids for noncancer pain: results from the International Pharmacosurveillance Study. Pain 2024.

184 Bedson J., Chen Y., Ashworth J. et al., Risk of adverse events in patients prescribed long-term opioids: A cohort study in the UK Clinical Practice Research Datalink. European Journal of Pain 2019;23(5):908-22.

185 Elmoheen, A., Nazal, A.F., Zubaidi, O., et al., Expert review and recommendations for the management of acute, chronic, and neuropathic pain in Qatar. Qatar Medical Journal, 2021; (2), p.19. last accessed 6 January 2026)

186 Nagar V.R., Birthi P., Salles S., Sloan P.A., Opioid Use in Chronic Pain Patients with Chronic Kidney Disease: A Systematic Review. Pain medicine (Malden, Mass) 2017;18:1416–49. (last accessed 6 January 2026)

187 Mattia C., Luongo L., Innamorato M., et al., An Italian expert consensus on the use of opioids for the management of chronic non-oncological pain in clinical practice: focus on buprenorphine. Journal of Pain Research. 2021;14(3193-3206. (last accessed 6 January 2026)

188 Fenske, J.N., Berland, D.W., Chandran, S., et al., Ambulatory Pain Management Guideline 2021, University of Michigan. (last accessed 6 January 2026)

189 NICE Clinical Knowledge Summary Depression: Serotonin noradrenaline reuptake inhibitors (SNRIs), April 2025. (last accessed 6 January 2026)

190 Migliorini F., Maffulli N., Eschweiler J., et al., The pharmacological management of chronic lower back pain. Expert Opinion on Pharmacotherapy 2021;22(1):109-119. (last accessed 6 January 2026)

191 Enke, O., New, H.A., New, C.H., et al., Anticonvulsants in the treatment of low back pain and lumbar radicular pain: a systematic review and meta-analysis. Canadian Medical Association Journal, 2018; 190(26), pp.E786-E793. (last accessed 6 January 2026)

192 McDonagh M.S., Selph S.S., Buckley D.I., et al. Nonopioid Pharmacologic Treatments for Chronic Pain [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2020 Apr. (Comparative Effectiveness Review, No. 228.) Evidence Summary

193 Moore, R.A., Wiffen, P.J., Derry, S. and Rice, A.S., 2014. Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane database of systematic reviews, (4). (last accessed 6 January 2026)

194 Centre for Clinical Practice at NICE UK, 2013. Neuropathic pain: the pharmacological management of neuropathic pain in adults in non-specialist settings. Updated 2020. (last accessed 6 January 2026)

195 Derry, S., Cording, M., Wiffen, P.J., et al., 2016. Pregabalin for pain in fibromyalgia in adults. Cochrane Database of Systematic Reviews (9). (last accessed 6 January 2026)

196 National Records of Scotland 2025. Drug-related deaths in Scotland in 2024. (last accessed 6 January 2026)

197 UK Government, Medicines and Healthcare Products Regulatory Agency, Drug Safety Update, 2021. Pregabalin (Lyrica): findings of safety study on risks during pregnancy. (last accessed 6 January 2026)

198 UK Teratology Information Service monograph, Use of gabapentin in pregnancy, May 2024, revised September 2025. (last accessed 6 January 2026)

199 Mathieson, S., Maher, C.G., Ferreira, G.E., et al., Deprescribing opioids in chronic non-cancer pain: systematic review of randomised trials. Drugs, 2020; 80(15), pp.1563-1576. (last accessed 6 January 2026)

200 US Food and Drug Administration communication, FDA recommends health care professionals discuss naloxone with all patients when prescribing opioid pain relievers or medicines to treat opioid use disorder (last accessed 6 January 2026)

201 Coffin P.O., Behar E., Rowe C., et al., Nonrandomized Intervention Study of Naloxone Coprescription for Primary Care Patients Receiving Long-Term Opioid Therapy for Pain. Annals of Internal Medicine 2016;165:245-52.

202 Stratton, I.M., Adler, A.I., Neil, H.A.W., et al., Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ, 2000; 321(7258), pp.405-412. (last accessed 6 January 2026)

203 National Institute for Health and Clinical Excellence (NICE) Type 2 diabetes in adults: management guideline (NG 28) (2022 update). 2015. (last accessed 6 January 2026)

204 American Diabetes Association, 6. Glycemic targets: standards of medical care in diabetes—2021. Diabetes Care, 2021; 44(Supplement_1), pp.S73-S84. (last accessed 6 January 2026)

205 Knowler, W.C., Diabetes Prevention Program Research Group: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine, 2002; 346, pp.393-403. (last accessed 6 January 2026)

206 The Scottish Government, A Healthier Future: type 2 Diabetes prevention, early detection and intervention: framework, 2018. (last accessed 6 January 2026)

207 Scottish Intercollegiate Guidelines Network (SIGN), Pharmacological management of glycaemic control in people with type 2 diabetes. SIGN 154, 2017. (last accessed 6 January 2026)

208 Davies, M.J., Aroda, V.R., Collins, B.S., et al., Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia, 2022; pp.1-42. (last accessed 6 January 2026)

209 Medicines and Healthcare products Regulatory Agency, 2016. SGLT2 inhibitors: updated advice on the risk of diabetic ketoacidosis. Drug Safety Update, 9(9), p.1. (last accessed 6 January 2026)

210 Strain, W.D., Hope, S.V., Green, A., et al., 2018. Type 2 diabetes mellitus in older people: a brief statement of key principles of modern day management including the assessment of frailty. A national collaborative stakeholder initiative. Diabetic Medicine, 35(7), pp.838-845. (last accessed 6 January 2026)

211 National Institute for Health and Care Excellence (NICE) Clinical Knowledge Summary, Constipation, (January 2022). (last accessed 6 January 2026)

212 Rodríguez-Ramallo, H., Báez-Gutiérrez, N., Prado-Mel, E., et al., Association between Anticholinergic Burden and Constipation: A Systematic Review. In Healthcare 2021, (Vol. 9, No. 5, p. 581). MDPI. (last accessed 6 January 2026)

213 Brayfield A., Cadart C. (eds), Martindale: The Complete Drug Reference. London: Pharmaceutical Press. (last accessed 7 February 2025)

214 Kang, S.J., Cho, Y.S., Lee, T.H., et al., Medical management of constipation in elderly patients: Systematic review. Journal of Neurogastroenterology and Motility, 2021; 27(4), p.495. (last accessed 6 January 2026)

215 British National Formulary (November 2022). (last accessed 7 February 2025)

216 MHRA Drug Safety Update Clozapine: reminder of potentially fatal risk of intestinal obstruction, faecal impaction, and paralytic ileus, October 2017 (last accessed 6 January 2026)

217 Howland, R.H., Potential adverse effects of discontinuing psychotropic drugs: Part 1: Adrenergic, cholinergic, and histamine drugs. Journal of Psychosocial Nursing and Mental Health Services, 2010; 48(6), pp.11-14. (last accessed 6 January 2026)

218 National Institute for Health and Care Excellence Quality statement 4: Levodopa in hospital or a care home, February 2018. (last accessed 6 January 2026)

219 Lipanovic, D. ‘Every minute counts’: taking a national approach to time-critical medicines, The Pharmaceutical Journal, 24 October 2024. (last accessed 6 January 2026)

220 National Institute for Health and Care Excellence Guideline, Parkinson disease in adults: diagnosis and management [NG71], 2017 (Updated July 2019). (last accessed 6 January 2026)

221 Specialist Pharmacy Service, Parkinson’s disease medicines in swallowing difficulties, June 2022. (last accessed 6 January 2026)

222 Parkinson’s UK, Every minute counts: Time critical Parkinson’s medication on time, every time, September 2023. (last accessed 6 January 2026)

223 National Institute for Health and Care Excellence Clinical Knowledge Summaries, Scenario: Confirmed Parkinson's disease, Revised August 2023. (last accessed 6 January 2026)

224 National Institute for Health and Care Excellence, Depression in adults: treatment and management [NG 222], (June 2022). (last accessed 6 January 2026)

225 Cleare A, Pariante C.M., Young A.H. et al., Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines. Journal of psychopharmacology. 2015; 29 (5): 459-525.

226 National Institute for Health and Care, Excellence, Depression in adults: recognition and management [CG90], (October 2009). (last accessed 7 February 2025)

227 National Institute for Health and Care Excellence (NICE), Generalised anxiety disorder and panic disorder in adults: management [CG113], (June 2020). (last accessed 6 January 2026)

228 National Institute for Health and Care Excellence (NICE), Obsessive-compulsive disorder and body dysmorphic disorder: treatment [CG31], (November 2005). (last accessed 6 January 2026)

229 Taylor, D.M., Barnes, T.R.E. and Young, A.H. Depression and Anxiety Disorders. In The Maudsley Prescribing Guidelines in Psychiatry (eds D.M. Taylor, T.R.E. Barnes and A.H. Young), 2026.

230 National Institute for Health and Care Excellence (NICE), Anxiety Disorders. Quality Standards, (February 2014). (last accessed 6 January 2026)

231 National Institute for Health and Care Excellence, Social anxiety disorder: recognition, assessment and treatment, (May 2013). (last accessed 6 January 2026)

232 Medicines and Healthcare products Regulatory Agency, Drug Safety Update Benzodiazepines and opioids: reminder of risk of potentially fatal respiratory depression, 2020 (last accessed 6 January 2026)

233 National Institute for Health and Care Excellence (NICE), Medicines associated with dependence or withdrawal symptoms: safe prescribing and withdrawal managements for adults. [NG215], 2022. (last accessed 6 January 2026)

234 National Institute for Health and Care Excellence (NICE). Clinical Knowledge Summary. Benzodiazepine and z-drug withdrawal. Last revised May 2024. (last accessed 6 January 2026)

235 NHS Education for Scotland Once for Scotland Dementia resources. (last accessed 6 January 2026)

236 NICE TA 217 Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease. NICE 20 June 2018 (last accessed 6 January 2026)

237 Scottish Government, Dementia Strategy for Scotland: Everyone’s Story, 2023. (last accessed 6 January 2026)

238 Isik AT et al., Cardiovascular outcomes of cholinesterase inhibitors in individuals with dementia: a meta-analysis and systematic review. Journal of the American Geriatrics Society, 2018 Seo; 66 (9): 1805-1822 (last accessed 6 January 2026)

239 Alzheimer’s Society patient information: Non-drug approaches to changes in mood and behaviour, available on Alzheimer’s Society website (last accessed 6 January 2026)

240 Mental Welfare Commission for Scotland Good Practice Guide- Covert medication, (last accessed 6 January 2026)

241 Alzheimer Scotland patient information, for example Donepezil available on Alzheimer Scotland website (last accessed 6 January 2026)

242 Choice and Medication patient information, hosted on NHS 24 website. (last accessed 7 February 2025)

243 Choice and Medication website hosted by NHS 24, Alzheimer’s Disease and dementia, A handy chart to help you compare the medicines to help the symptoms of Alzheimer’s Disease. ©2024 MisturaTM Enterprise Ltd (last accessed 7 February 2025)

244 Woodall A., Gampel A., Walker L.E., et al. Antipsychotic management in general practice: serial cross-sectional study (2011–2020). British Journal of General Practice 2025;75(750):e68-e79. (last accessed 6 January 2026)

245 Woodall A, Buchan I, Walker LE, et al. ‘Flattened, fattened, and forgotten’: the ‘dis-integrated’ care of patients prescribed antipsychotics in the UK. British Journal of General Practice 2025;75(750):9-10. doi: 10.3399/bjgp25X740397

246 Johnson C.F., Ingram F., Thomson F., et al. General practice pharmacist-led antipsychotic physical health monitoring: a prospective intervention scoping study. Family Practice 2024;41(1):41-49. doi: 10.1093/fampra/cmad120

247 Public Health England, Severe mental illness (SMI) and physical health inequalities: briefing, 2018. (last accessed 6 January 2026)

248 National Institute for Health and Care Excellence (NICE). Psychosis and schizophrenia in adults: prevention and management [CG178]. 2014. (last accessed 6 January 2026)

249 Pillinger T., McCutcheon R.A., Vano L., et al. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry. 2020. (last accessed 6 January 2026)

250 National Institute for Health and Care Excellence (NICE) BNF Treatment Summaries: Psychoses and related disorders (last accessed 6 January 2026)

251 Royal College of Psychiatrists. The risks and benefits of high-dose antipsychotic medication, CR190, 2014; revised January 2023) (last accessed 6 January 2026)

252 National Institute for Health and Care Excellence (NICE). Psychosis and schizophrenia in children and young people: recognition and management CG155. 2013, last updated 2016. (last accessed 6 January 2026)

253 National Institute for Health and Care Excellence (NICE), Psychosis and schizophrenia in adults [QS80], 2015. (last accessed 6 January 2026)

254 Medicines and Healthcare products Regulatory Agency, Antipsychotic medicines: licensed products, uses and side effects, 2005. (last accessed 6 January 2026)

255 Medicines and Healthcare products Regulatory Agency, Drug Safety Update Antipsychotics: risk of venous thromboembolic events, 2014. (last accessed 6 January 2026)

256 National Institute for Health and Care Excellence (NICE) website, BNF Clozapine (last accessed 6 January 2026)

257 Marston L., Nazareth I., Petersen I., et al. Prescribing of antipsychotics in UK primary care: a cohort study. BMJ Open 2014;4(12):e006135. (last accessed 6 January 2026)

258 National Institute for Health and Care Excellence (NICE) Borderline personality disorder: recognition and management [CG78]. 2009 (last accessed 6 January 2026)

259 National Institute for Health and Care Excellence (NICE), Challenging behaviour and learning disabilities: prevention and interventions for people with learning disabilities whose behaviour challenges [NG11], 2015. (last accessed 6 January 2026)

260 National Institute for Health and Care Excellence (NICE), Delirium, diagnosis and management [CG103]. 2010. Last updated 2019. (last accessed 6 January 2026)

261 Muhlbauer V., Mohler R., Dichter M.N., et al., Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia. The Cochrane database of systematic reviews. 2021;12 CD013304.

262 Lonergan E., Luxenberg J., Colford J.M. et al., Haloperidol for agitation in dementia. Cochrane Database of Systematic Reviews 2002, Issue 2. Art. No.: CD002852. DOI: 10.1002/14651858.CD002852. (last accessed 6 January 2026)

263 Burry L., Mehta S., Perreault M.M., et al., Antipsychotics for treatment of delirium in hospitalised non-ICU patients. The Cochrane database of systematic reviews. 2018;6 CD005594.

264 Bjerre L.M., Farrell B., Hogel M., et al., Deprescribing antipsychotics for behavioural and psychological symptoms of dementia and insomnia: Evidence-based clinical practice guideline. Canadian Family Physician. 2018;64(1):17-27.

265 Miarons Font M., Marin Rubio S., Perez Cordon L., et al., Evidence and decision algorithm for the withdrawal of antipsychotic treatment in the elderly with dementia and neuropsychiatric symptoms. European Journal of Hospital Pharmacy. 2018;25 (Supplement 1):A205.

266 Department of Health Ireland. Appropriate prescribing of psychotropic medication for non-cognitive symptoms in people with dementia. 2019. (last accessed 6 January 2026)

267 Scottish Intercollegiate Guidelines Network (SIGN), Risk reduction and management of delirium, SIGN 157, 2019. (last accessed 6 January 2026)

268 Lesley Cooper, Jenny Harbour, Jacqueline Sneddon, R. Andrew Seaton, Safety and efficacy of de-labelling penicillin allergy in adults using direct oral challenge: a systematic review, JAC-Antimicrobial Resistance, Volume 3, Issue 1, March 2021, dlaa123, (last accessed 6 January 2026)

269 UK Government, Confronting antimicrobial resistance 2024 to 2029, May 2014. (last accessed 6 January 2026)

270 Antimicrobial Resistance and Healthcare Associated Infection (ARHAI) Scotland. Scottish One Health Antimicrobial Use and Antimicrobial Resistance in 2023. (last accessed 6 January 2026)

271 Savic L., Ardern-Jones M., Avery A., et al. BSACI guideline for the set-up of penicillin allergy de-labelling services by non-allergists working in a hospital setting. Clinical and Experimental Allergy. 2022; 52: 1135-1141. (last accessed 6 January 2026)

272 Savic L., Thomas C., Fallaha D., et al., DALES, Drug Allergy Labels in Elective Surgical patients: a prospective multicentre cross-sectional study of incidence, risks, and attitudes in penicillin de-labelling strategies, British Journal of Anaesthesia, Volume 125, Issue 6, 2020, Pages 962-969, ISSN 0007-0912. (last accessed 6 January 2026)

273 Scottish Antimicrobial Prescribing Group, Penicillin Allergy De-labelling. (last accessed 6 January 2026)

274 General Medical Council, Treatment and care towards the end of life: good practice in decision making, 2010, updated 2022. (last accessed 6 January 2026)

275 DynaMed. Adverse Effects of Antidepressant Medication. EBSCO Information Services. (last accessed 6 January 2026)

276 DynaMed. Nonsteroidal Anti-inflammatory Drugs (NSAIDs) Overview. EBSCO Information Services. (last accessed 6 January 2026)

277 NICE Clinical Knowledge Summary, Depression, Selective serotonin reuptake inhibitors (SSRIs), April 2025. (last accessed 6 January 2026)

278 National Institute for Health and Care Excellence, Clinical Knowledge Summaries, Scenario: Acute gout, (June 2023). (last accessed 6 January 2026)

279 Medicines Complete website, Fluoxetine Hydrochloride. (last accessed 7 February 2025)

280 Medicines Complete website, Stockley's Drug Interactions, NSAIDs + SSRIs or SNRIs. (last accessed 7 February 2025)

281 NICE Antiplatelet Treatment Revised May 2025 (last accessed 6 January 2026)

282 National Institute for Health and Care Excellence (NICE) Guideline Venous Thromboembolic diseases: diagnosis, management and thrombophilia testing, [NG158] 2020, updated 2023. (last accessed (last accessed 6 January 2026)

283 National Institute for Health and Care Excellence (NICE) Guideline Acute Coronary Syndromes, NG185, 2020. (last accessed (last accessed 6 January 2026)

284 Scottish Intercollegiate Guideline Network (SIGN), Acute Coronary Syndrome, SIGN 148 July 2016. (last accessed 6 January 2026)

285 National Institute for Health and Care Excellence (NICE) Guideline Atrial Fibrillation Diagnosis and management, NG196, June 2021. (last accessed 6 January 2026)

286 van Rein N., Heide-Jørgensen U., Lijfering W.M., et al., Major Bleeding Rates in Atrial Fibrillation Patients on Single, Dual, or Triple Antithrombotic Therapy. Circulation. 2019 Feb 5;139(6):775-786.

287 Levine G.N., Bates E.R., Bittl J.A., et al., ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Journal of Thoracic and Cardiovascular Surgery. 2016 Nov;152(5):1243-75.

288 Valgimigli M., Bueno H., Byrne R.A., et al., ESC Scientific Document Group; ESC Committee for Practice Guidelines (CPG); ESC National Cardiac Societies. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal. 2018 Jan 14;39(3):213-60

289 NICE Clinical Knowledge Summary, Antiplatelet Treatment, Scenario: Antiplatelet treatment for secondary prevention of cardiovascular disease (CVD) Revised May 2025 (last accessed 6 January 2026)

290 Ahn H-J., Lee S-R., Choi E-K., et al. Protective effect of proton-pump inhibitor against gastrointestinal bleeding in patients receiving oral anticoagulants: A systematic review and meta-analysis. British Journal of Clinical Pharmacology. 2022;88(11):4676‐4687

291 Summary of Product Characteristics of medications accessed from electronic medicines compendium. (last accessed 6 January 2026)

292 BPAC NZ Limited (bpac^nz), Avoiding the “triple whammy” in primary care: ACE inhibitor/ARB + diuretic + NSAID, 2018. (last accessed 6 January 2026)

293 National Institute of Health and Care Excellence (NICE), Clinical Knowledge Summary, Diabetes - type 2: Metformin, 2024, revised July 2025. (last accessed 6 January 2026)

294 Pazhayattil G.S., Shirali A.C., Drug-induced impairment of renal function. International Journal of Nephrology and Renovascular Disease. 2014 Dec 12;7:457-68. doi: 10.2147/IJNRD.S39747. PMID: 25540591; PMCID: PMC4270362.

295 Medicines Complete website, Stockley's Drug Interactions, Angiotensin II receptor antagonists + Diuretics; Loop, Thiazide and related. (last accessed 7 February 2025)

296 BMJ Publishing Group Ltd, BMJ Best Practice, Acute Kidney Injury, 2024. (last accessed 6 January 2026)

297 National Institute of Health and Care Excellence (NICE), Clinical Knowledge Summaries, Chronic kidney disease, revised May 2025. (last accessed 6 January 2026)

298 National Institute of Health and Care Excellence (NICE), Neuropathic pain in adults: pharmacological management in non-specialist settings, CG173, 2013, updated September 2020. (last accessed 6 January 2026)

299 Musich, S, et al., Concurrent Use of Opioids with Other Central Nervous System-Active Medications Among Older Adults, Population Health Management, 2020. (last accessed 6 January 2026)

300 National Institute of Health and Care Excellence (NICE), Clinical Knowledge Summaries, Chronic pain, January 2024, revised January 2025. (last accessed 6 January 2026)

301 National Institute of Health and Care Excellence (NICE), Clinical Knowledge Summaries, Analgesia - mild-to-moderate pain, 2021, revised August 2025. (last accessed 6 January 2026)

302 United States Food and Drug Administration, Drug Safety Communications, FDA warns about serious breathing problems with seizure and nerve pain medicines gabapentin (Neurontin, Gralise, Horizant) and pregabalin (Lyrica, Lyrica CR) When used with CNS depressants or in patients with lung problems, December 2019. (last accessed 6 January 2026)

303 Medicines Complete website, Stockley's Drug Interactions, SSRIs + Opioids; Tramadol, October 2018. (last accessed 7 February 2025)

304 Medicines Complete website, Stockley's Drug Interactions, Opioids; Tramadol + Mirtazapine, October 2018. (last accessed 7 February 2025)

305 Hai-Yin Jiang, Hua-Zhong Chen, Xin-Jun Hu, et al., Use of Selective Serotonin Reuptake Inhibitors and Risk of Upper Gastrointestinal Bleeding: A Systematic Review and Meta-analysis, Clinical Gastroenterology and Hepatology, Volume 13, Issue 1, 2015, Pages 42-50.e3, ISSN 1542-3565. (last accessed 6 January 2026)

306 Scottish Government, Managing Multiple Medicines website (last accessed 7 February 2025)

307 NICE Clinical Knowledge Summaries. Diabetes Type 2. Scenario: Management – adults. (last accessed 6 January 2026)

308 The Renal Association. Clinical Practice Guideline. Acute Kidney Injury. 2019. (last accessed 6 January 2026)

309 Association of British Clinical Diabetologists (ABCD) and the Renal Association Clinical practice guidelines for management of hypertension and renin-angiotensin-aldosterone system blockade in adults with diabetic kidney disease, 2021 update. (last accessed 6 January 2026)

310 Watson, K.E., Dhaliwal, K., Mcmurtry, E., al., Sick Day Medication Guidance for People With Diabetes, Kidney Disease, or Cardiovascular Disease: A Systematic Scoping Review, 2022. Kidney Medicine, Volume 4, Issue 9, 100491 Cambridge, MA. (last accessed 6 January 2026)

311 Whiting, P., Morden, A., Tomlinson, L.A., et al., What are the risks and benefits of temporarily discontinuing medications to prevent acute kidney injury? A systematic review and meta-analysis, BMJ Open 2017;7:e012674. doi:10.1136/bmjopen-2016- 012674. (last accessed 6 January 2026)

312 “Sick day” guidance in patients at risk of Acute Kidney Injury: a Position Statement from the Think Kidneys Board. (last accessed 6 January 2026)

313 PrescQIPP, Bulletin 260 Acute Kidney Injury (AKI) – Sick Day Guidance. (last accessed 6 January 2026)

314 NICE Clinical Knowledge Summaries. Acute kidney injury: Scenario: Prevention of acute kidney injury. (last accessed 6 January 2026)

315 BMJ Best Practice, Diabetic ketoacidosis. (last accessed 6 January 2026)

316 MHRA Drug Safety Update, SGLT2 inhibitors: monitor ketones in blood during treatment interruption for surgical procedures or acute serious medical illness, March 2020. (last accessed 6 January 2026)

317 National Institute of Health and Care Excellence (NICE), Acute kidney injury: prevention, detection and management, [NG148], 2019, updated October 2024. (last accessed 6 January 2026)

318 NHS UK website, Acute kidney injury. (last accessed 6 January 2026)

319 Management of Postmenopausal Osteoporosis: American College of Obstetricians and Gynecologists Clinical Practice Guideline No. 2. Obstetrics & Gynecology 139(4):p 698-717, April 2022. | DOI: 10.1097/AOG.0000000000004730

320 Shoback, D., Rosen, C.J., Black, D.M., et al., Pharmacological management of osteoporosis in postmenopausal women: an endocrine society guideline update. The Journal of Clinical Endocrinology & Metabolism, 2020; 105(3), pp.587-594.

321 Eastell, R., Rosen, C.J., Black, D.M., et al., Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism, 2019; 104(5), pp.1595-1622.

322 Gregson, C.L., Armstrong, D.J., Bowden, J., et al., UK clinical guideline for the prevention and treatment of osteoporosis. Archives of osteoporosis, 2022; 17(1), p.58.

323 Cedeno-Veloz, B.A., Erviti Lopez, J., Gutiérrez-Valencia, M., et al., Efficacy of Antiresorptive Treatment in Osteoporotic Older Adults: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. The Journal of Nutrition, Health & Aging, 2022; 26(8), pp.778-785.

324 Deardorff, W.J., Cenzer, I., Nguyen, B. et al., Time to benefit of bisphosphonate therapy for the prevention of fractures among postmenopausal women with osteoporosis: a meta-analysis of randomized clinical trials. JAMA Internal Medicine, 2022; 182(1), pp.33-41.

325 Fan, Q. and Wang, J., The efficacy and safety of bisphosphonates for osteoporosis in women older than 65 years: a meta-analysis. Current Pharmaceutical Design, 2020; 26(32), pp.4022-4030.

326 Fatoye, F., Smith, P., Gebrye, T. et al., Real-world persistence and adherence with oral bisphosphonates for osteoporosis: a systematic review. BMJ open, 2019; 9(4), p.e027049.

327 Lamarre, M., Marcotte, M., Laurin, D., et al., Discontinuation of bisphosphonates in seniors: a systematic review on health outcomes. Archives of Osteoporosis, 2021; 16, pp.1-23.

328 Wang, Q.Y., Ding, N., Dong, Y.H., et al., Pharmacological treatment of osteoporosis in elderly people: a systematic review and meta-analysis. Gerontology, 2021; 67(6), pp.639-649.

329 Wells, G.A., Hsieh, S.C., Zheng, C., et al., Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database of Systematic Reviews, 2022; (5).

330 Medicines and Healthcare products Regulatory Agency, Drug Safety Update volume 14, issue 1: August 2020: 3. (last accessed 6 January 2026)

331 Yamaguchi, Y., Morita, T. and Kumanogoh, A., The therapeutic efficacy of denosumab for the loss of bone mineral density in glucocorticoid-induced osteoporosis: a meta-analysis. Rheumatology Advances in Practice, 2020; 4(1), p.rkaa008

332 Medicines Healthcare products Regulatory Agency, Denosumab 60mg (Prolia): increased risk of multiple vertebral fractures after stopping or delaying ongoing treatment, August 2020 (last accessed 6 January 2026)

333 National Osteoporosis Guideline Group (NOGG), Clinical guideline for the prevention and treatment of osteoporosis, section 7: Strategies for management of osteoporosis and fracture risk, 2024. (last accessed 6 January 2026)

334 Royal Pharmaceutical Society, Multi-compartment compliance aids Pharmacy Guide, September 2022. (last accessed 6 January 2026)

335 NHS Lanarkshire, Guideline for deprescribing in patients with a shortened life expectancy across NHS Lanarkshire, October 2023. (last accessed 6 January 2026)

336 British National Formulary, Medicines Guidance, Prescribing in palliative care. (last accessed 6 January 2026)

337 The Palliative Care Formulary. (last accessed 7 February 2025)

338 Robinson-Barella et al. Starting to think that way from the start”: approaching deprescribing decision making for people accessing palliative care - a qualitative exploration of healthcare professionals views. BMC Palliative Care, 2024; 23:221. (last accessed 6 January 2026)

339 Thompson J. Deprescribing in palliative care. Clinical Medicine (Lond). 2019 Jul;19(4):311-314. doi: 10.7861/clinmedicine.19-4-311. PMID: 31308110; PMCID: PMC6752237. (last accessed 6 January 2026)

340 Bennett M.I., Smith B.H., Torrance N., Potter J.. The S-LANSS score for identifying pain of predominantly neuropathic origin: validation for use in clinical and postal research. J Pain. 2005 Mar;6(3):149-58.

341 SAPG Decision aid for diagnosis and management of suspected urinary tract infection (UTI) in people aged 65 years and over, March 2021. (last accessed 6 January 2026)

342 Medicines Healthcare products Regulatory Agency, Drug Safety Update, Nitrofurantoin now contraindicated in most patients with an estimated glomerular filtration rate (eGFR) of less than 45 ml/min/1.73m², February 2015. (last accessed 6 January 2026)

343 Society for endocrinology, Steroid sick day rules patient information leaflet. (last accessed 6 January 2026)

344 Trend Diabetes, End of Life Guidance for Diabetes Care, November 2021. (last accessed 6 January 2026)

345 Musini V.M., Tejani A.M., Bassett K., et al., Pharmacotherapy for hypertension in adults 60 years or older. Cochrane Database of Systematic Reviews. 2019(6)

346 Musini V.M., Gueyffier F., Puil L., et al., Pharmacotherapy for hypertension in adults aged 18 to 59 years. Cochrane Database of Systematic Reviews. 2017(8)

347 Wright J.M., Musini V.M., Gill R., First‐line drugs for hypertension. Cochrane Database of systematic reviews. 2018(4)

348 The Consensus Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. The New England Journal of Medicine. 1987; 316(23): 1429-1435

349 The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The New England Journal of Medicine 1991; 325(5): 293-302

350 Bowling C.B., Sanders P.W., Allman R.M., Rogers W.J et al. Effects of enalapril in systolic heart failure patients with and without chronic kidney disease: Insights from the SOLVD Treatment trial. International Journal of Cardiology. 2013; 167 (1): 151-156

351 The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The New England Journal of Medicine. 1992; 327 (10): 685 – 691

352 Aronow W.S., Shamliyan T.A., Benefits and harms of sacubitril in adults with heart failure and reduced left ventricular ejection fraction. The American Journal of Cardiology. 2017 Oct 1;120(7):1166-70.

353 Pitt B., Zannad F., Remme W.J., et al., The effect of spironolactone on morbidity and mortality in patients with severe heart failure. New England Journal of Medicine. 1999 Sep 2;341(10):709-17

354 The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. The Lancet. 1999;353(9146):9-13

355 Mant J., Hobbs F.D., Fletcher K., et al., Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 2007; 370: 493 – 503

356 Baigent C., Blackwell L., Collins R., et al., Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373(9678):1849-60.. Lancet 2009; 373: 1849-60

357 Antithrombotic trialists collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, MI and stroke in high risk patients. BMJ 2002;358:71-86

358 McGrath E., O’Conghaile A., Eikelboom J.W., et al., Validity of composite outcomes in meta-analyses of stroke prevention trials: the case of aspirin. Cerebrovascular Diseases. 2011;32(1):22-7

359 De Schryver E.L., Algra A, van Gijn J., Dipyridamole for preventing stroke and other vascular events in patients with vascular disease. Cochrane Database of Systematic Reviews. 2007(3)

360 Sim R., Chong C.W., Loganadan N.K., et al., Comparative effectiveness of cardiovascular, renal and safety outcomes of second‐line antidiabetic drugs use in people with type 2 diabetes: A systematic review and network meta‐analysis of randomised controlled trials. Diabetic Medicine. 2022 Mar;39(3):e14780

361 McKee A., Al-Khazaali A., Albert S.G., Glucagon-like peptide-1 receptor agonists versus sodium-glucose cotransporter inhibitors for treatment of T2DM. Journal of the Endocrine Society. 2020 May;4(5):bvaa037

362 Albert S.G., Wood E.M., Ahir V., Glucagon-like peptide 1-receptor agonists and A1c: Good for the heart but less so for the eyes? Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2023 Jan 1;17(1):102696

363 Aronow W.S., Shamliyan T.A., Comparative effectiveness and safety of empagliflozin on cardiovascular mortality and morbidity in adults with type 2 diabetes. Annals of Translational Medicine. 2017 Dec;5(23)

364 Jiang M., Liu Q., Jiang T., et al., Adding Sodium–Glucose Co-Transporter 2 Inhibitors to Sulfonylureas and Risk of Hypoglycemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Frontiers in Endocrinology. 2021:1365

365 Lo K.B., Gul F., Ram P., et al., The effects of SGLT2 inhibitors on cardiovascular and renal outcomes in diabetic patients: a systematic review and meta-analysis. Cardiorenal medicine. 2020;10(1):1-0

366 Martínez-Vizcaíno V., Díez-Fernández A., Álvarez-Bueno C., et al., Safety and efficacy of SGLT2 inhibitors: a multiple-treatment meta-analysis of clinical decision indicators. Journal of Clinical Medicine. 2021 Jun 19;10(12):2713

367 UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with Sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-53

368 UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998; 352: 854-65

369 ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. New England Journal of Medicine. 2008 Jun 12;358(24):2560-72

370 Yang X.C., Shao L.L., Mi Y.J., et al., Effect of renin-angiotensin-aldosterone system inhibitors on all-cause mortality and major cardiovascular events in patients with diabetes: A meta-analysis focusing on the number needed to treat and minimal clinical effect. Journal of Diabetes and its Complications. 2021 Mar 1;35(3):107830

371 Towheed T., Maxwell L., Judd M., et al., Acetaminophen for osteoarthritis. Cochrane Database of Systematic Reviews. 2006(1)

372 Derry S., Wiffen P.J., Moore R.A., Aspirin for acute treatment of episodic tension‐type headache in adults. Cochrane Database of Systematic Reviews. 2017(1)

373 Health Services Safety Investigation Body, Potential under-recognised risk of harm from the use of propranolol, February 2020. (last accessed 6 January 2026)

374 National Institute for Health and Care Excellence (NICE), Urinary tract infection (lower): antimicrobial prescribing, NICE guideline [NG109]. Published: 31 October 2018. (last accessed 6 January 2026)

375 Scottish Antimicrobial Prescribing Group (SAPG) website, ‘Antibiotic Awareness’. 2025. (last accessed 6 January 2026)

376 Scottish Government, Medicines - achieving value and sustainability in prescribing: guidance, 2024. (last accessed 6 January 2026)

377 Scottish Intercollegiate Guidelines Network 160. Management of suspected bacterial lower urinary tract infections in adult women, 2020. (last accessed 6 January 2026)

378 Scottish Government, Type 2 Diabetes Mellitus - quality prescribing strategy: improvement guide 2024 to 2027, 2024. (last accessed 6 January 2026)

379 British National Formulary website, 2025. (last accessed 6 January 2026)

380 Scottish Atlas of Healthcare variation. Mental Health Dashboard. Antipsychotic prescribing 75+. September 2019. (last accessed 7 May 2025)

381 National Institute for Health and Care Excellence Guideline NG245: Asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN), November 2024. (last accessed 6 January 2026)

382 Dreischulte, T., Grant, A.M., McCowan, C. et al. Quality and safety of medication use in primary care: consensus validation of a new set of explicit medication assessment criteria and prioritisation of topics for improvement. BMC Clinical Pharmacology 12, 5 (2012) https://doi.org/10.1186/1472-6904-12-5

383 By the 2023 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2023; 71(7): 2052-2081. doi:10.1111/jgs.18372

384 O’Mahony, D., Cherubini, A., Guiteras, A.R. et al. STOPP/START criteria for potentially inappropriate prescribing in older people: version 3. European Geriatric Medicine 14, 625–632 (2023). (last accessed 6 January 2026)

385 Scottish Intercollegiate Guidelines Network Methodology checklist: systematic reviews and meta-analyses, 2021. (last accessed 6 January 2026)

386 Brouwers M., Kho M.E., Browman G.P., et al., on behalf of the AGREE Next Steps Consortium. AGREE II: Advancing guideline development, reporting and evaluation in healthcare. Canadian Medical Association Journal. Dec 2010, 182:E839-842; doi: 10.1503/cmaj.090449

387 Scottish Intercollegiate Guidelines Network. A guideline developer’s handbook Revised edition published 2019. (last accessed 6 January 2026)

388 OECD/European Commission, Health at a Glance: Europe 2024: State of Health in the EU Cycle, 2024. Paris: OECD Publishing. 10.1787/b3704e14-en. (last accessed 6 January 2026)

389 Raymond, A., Watt, T., Douglas, H. R., et al., Health inequalities in 2040. Current and projected patterns of illness by deprivation in England, 2024, The Health Foundation. (last accessed 6 January 2026)

390 Lucyk, K., & McLaren, L., Taking stock of the social determinants of health: a scoping review. PLoS ONE, 2017; 12(5), e0177306. 10.1371/journal.pone.0177306

391 McCartney, G., Dickie, E., Escobar, O., & Collins, C., Health inequalities, fundamental causes and power: towards the practice of good theory. Sociology of Health and Illness, 2020; 43(1), 20–39. 10.1111/1467-9566.13181

392 National Institute for Health and Care Excellence, NICE and Health Inequalities, 2024. URL: (last accessed 6 January 2026)

393 Krauth, S. J., Steell, L., Ahmed, S., et al., Association of latent class analysis-derived multimorbidity clusters with adverse health outcomes in patients with multiple long-term conditions: comparative results across three UK cohorts. eClinicalMedicine, 2024; 74, 10.1016/j.eclinm.2024.102703

394 Stannard, S., Holland, E., Crozier, S. R., et al., Early-onset burdensome multimorbidity: an exploratory analysis of sentinel conditions, condition accrual sequence and duration of three long-term conditions using the 1970 British Cohort Study. BMJ. 2022; 10.1136/bmjopen-2021-059587

395 Roberts, A., & Richards, G. C., Is England facing an opioid epidemic? British Journal of Pain, 2023; 17(3)10.1177/20494637231160684

396 Torrance, N., Veluchamy, A., Zhou, Y., et al., Trends in gabapentinoid prescribing, co-prescribing of opioids and benzodiazepines, and associated deaths in Scotland. British Journal of Anaesthesia, 2020; 125(2), 159. 10.1016/j.bja.2020.05.017

397 Woodward, A., Davies, N., Walters, K., et al., Self-management of multiple long-term conditions: A systematic review of the barriers and facilitators amongst people experiencing socioeconomic deprivation. PloS One, 2023; 18(2), e0282036. 10.1371/journal.pone.0282036

398 Craig, K. D., Holmes, C., Hudspith, M., et al., Pain in persons who are marginalized by social conditions. Pain, 2019; 161(2)10.1097/j.pain.0000000000001719

399 Macgregor, C., Walumbe, J., Tulle, E., et al., Intersectionality as a theoretical framework for researching health inequities in chronic pain. British Journal of Pain, 2023; 17(5)10.1177/20494637231188583

400 Scottish Government, Scottish Health Survey 2022 main report – volume 1, 2023. (last accessed 6 January 2026)

401 Public Health England, Chronic pain in adults 2017. Health survey for England, 2020.

402 Fayaz, A., Croft, P., Langford, R. M., et al., Prevalence of chronic pain in the UK: a systematic review and meta-analysis of population studies. BMJ Open, 2016; 6(6), e010364. 10.1136/bmjopen-2015-010364

403 Keogh, E., The gender context of pain. Health Psychology Review, 2021; 15(3), 454–481. 10.1080/17437199.2020.1813602

404 Gatchel, R. J., Peng, Y. B., Peters, M. L., et al., The biopsychosocial approach to chronic pain: Scientific advances and future directions. Psychological Bulletin, 2007; 133(4), 581. 10.1037/0033-2909.133.4.581

405 Pincus, T., Kim Burton, A., Vogel, S., and Field, A. P., A Systematic Review of Psychological Factors as Predictors of Chronicity/Disability in Prospective Cohorts of Low Back Pain. SPINE, 2002; 27(5)10.1097/00007632-200203010-00017

406 Hughes, K., Bellis, M. A., Hardcastle, K. A., et al., The effect of multiple adverse childhood experiences on health: a systematic review and meta-analysis. Lancet Public Health, 2017; 2, e356–e366

407 Allen, J., Balfour, R., Bell, R., et al., Social determinants of mental health. International Review of Psychiatry, 2014; 26(4), 392–407. 10.3109/09540261.2014.928270

408 Doebl, S., Macfarlane, G. J., and Hollick, R. J., “No one wants to look after the fibro patient”. Understanding models, and patient perspectives, of care for fibromyalgia: reviews of current evidence. Pain, 2020; 161(8)10.1097/j.pain.0000000000001870

409 Macgregor, C., Blane, D. N., Tulle, E., et al., An ecosystem of accepting life with chronic pain: A meta-ethnography. British Journal of Pain, 2024; 18(4)10.1177/20494637241250271

410 Toye, F., Seers, K., Allcock, N., et al., Patients’ experiences of chronic non-malignant musculoskeletal pain: a qualitative systematic review. British Journal of General Practice, 2013; 63(617), e829. 10.3399/bjgp13x675412

411 Cheetham, M., Moffatt, S., Addison, M., and Wiseman, A., Impact of Universal Credit in North East England: a qualitative study of claimants and support staff. BMJ. 2019; 10.1136/bmjopen-2019-029611

412 Morgan, C. L., Conway, P., and Currie, C. J., The relationship between self‐reported severe pain and measures of socio‐economic disadvantage. European Journal of Pain, 2011; 15(10), 1107. 10.1016/j.ejpain.2011.04.010

413 Farmer, C., Fenu, E., O’flynn, N., and Guthrie, B., Clinical assessment and management of multimorbidity: summary of NICE guidance. BMJ. 2016; 10.1136/bmj.i4843

414 May, C. R., Eton, D. T., Boehmer, K., et al., Rethinking the patient: using burden of treatment theory to understand the changing dynamics of illness. BMC Health Services Research, 2014; 14(1), 281. 10.1186/1472-6963-14-281

415 Smith, J. A., and Osborn, M., Pain as an assault on the self: An interpretative phenomenological analysis of the psychological impact of chronic benign low back pain. Psychology and Health, 2007; 22(5), 517. 10.1080/14768320600941756

416 Webster, F., Connoy, L., Sud, A., et al., (2023). Chronic struggle: an institutional ethnography chronic pain and marginalization. The Journal of Pain, 24(3), 437–448. 10.1016/j.jpain.2022.10.004

417 Blane, D., Lunan, C., Bogie, J., et al., Tackling the inverse care law in Scottish General Practice Policies, interventions and the Scottish Deep End Project. University of Glasgow, University of Edinburgh, 2024. (last accessed 6 January 2026)

418 Jain, S., Jadwani, V., Spogmy, S., and Walumbe, J. Inequalities and inequities in the types of chronic pain services available in areas of differing deprivation across England. Scandinavian Journal of Pain, 2022; 23(1), 168–174. 10.1515/sjpain-2022-0015

419 Moore, F. R., Williams, L., and Dunbar, M., Sociodemographic predictors of attendance at a Scottish pain management programme. British Journal of Pain, 2021; 15(4), 393–400. 10.1177/2049463720970579

420 Dixon-Woods, M., Cavers, D., Agarwal, S., et al., Conducting a critical interpretive synthesis of the literature on access to healthcare by vulnerable groups. BMC Medical Research Methodology, 2006; 6(1), 35. 10.1186/1471-2288-6-35

421 Robertson, R., Blythe, N., and Jeffries, D. Tackling health inequalities on NHS waiting lists, 2023, The Kings Fund. (last accessed 6 January 2026)

422 Arthritis and Musculoskeletal Alliance. Act Now: Musculoskeletal Health Inequalities and Deprivation, 2024. (last accessed 6 January 2026)

423 Gkiouleka, A., Wong, G., Sowden, S., et al., Reducing health inequalities through general practice: a realist review and action framework. Health and Social Care Delivery Research, 2024; 12(7)10.3310/ytww7032

424 Metzl, J. M., and Hansen, H., Structural competency: Theorizing a new medical engagement with stigma and inequality. Social Science and Medicine, 2013; 103, 126. 10.1016/j.socscimed.2013.06.032

425 Laskawska, M. S., Hébert, H. L., Richardson, C., et al., The core minimum dataset for measuring pain outcomes in pain services across Scotland. Developing and testing a brief multi-dimensional questionnaire. British Journal of Pain, 2022; 16(5), 504–517. 10.1177/20494637221092907

426 Lunn, A. D., Lynch, H., Bilaal, A., et al., What works: Addressing inequalities in the primary and secondary outpatient interface, Health Equity Centre, 2024. (last accessed 6 January 2026)

427 Baker, R., Freeman, G. K., Haggerty, J. L., et al., Primary medical care continuity and patient mortality: a systematic review. British Journal of General Practice, 2020; 70(698), e600. 10.3399/bjgp20x712289

428 Palmer, W., Hemmings, N., Rosen, R., et al., Improving access and continuity in general practice. Evidence review, 2018, Nuffield Trust. (last accessed 6 January 2026)

429 Dickie, E., Hearty, W., Fraser, A., et al., Power – a health and social justice issue, 2015. Edinburgh: NHS Scotland.

430 Protheroe, J., Brooks, H., Chew-Graham, C., et al., ‘Permission to participate?’ A qualitative study of participation in patients from differing socio-economic backgrounds. Journal of Health Psychology, 2012; 18(8)10.1177/1359105312459876

431 Brady, B., Veljanova, I., & Chipchase, L., An exploration of the experience of pain among culturally diverse migrant communities. Rheumatology Advances in Practice, 2017; 1(1), rkx002. 10.1093/rap/rkx002

432 Brady, B., Veljanova, I., & Chipchase, L., The Intersections of Chronic Noncancer Pain: Culturally Diverse Perspectives on Disease Burden. Pain Medicine, 2019; 20(3), 434–445. 10.1093/pm/pny088s

433 Browne, A. J., Varcoe, C., Ford-Gilboe, M., et al., Disruption as opportunity: Impacts of an organizational health equity intervention in primary care clinics. International Journal for Equity in Health, 2018; 17(1)10.1186/s12939-018-0820-2

434 Walters, R., Leslie, S. J., Polson, R., et al., Establishing the efficacy of interventions to improve health literacy and health behaviours: a systematic review. BMC Public Health, 2020; 20(1)10.1186/s12889-020-08991-0

435 World Health Organisation, Health Literacy, 2024. (last accessed 6 January 2026)

436 Brady, B., Andary, T., Pang, S. M., et al., A Mixed-Methods Investigation into Patients’ Decisions to Attend an Emergency Department for Chronic Pain. Pain Medicine, 2021; 22(10)10.1093/pm/pnab081

437 Lacey, R. J., Campbell, P., Lewis, M., and Protheroe, J., The Impact of Inadequate Health Literacy in a Population with Musculoskeletal Pain. HLRP: Health Literacy Research and Practice, 2018; 2(4)10.3928/24748307-20181101-01

438 Mackey, L. M., Doody, C., Werner, E. L., and Fullen, B., Self-Management Skills in Chronic Disease Management. Medical Decision Making, 2016; 36(6)10.1177/0272989x16638330

439 Mackey, L. M., Blake, C., Casey, M., et al., The impact of health literacy on health outcomes in individuals with chronic pain: a cross-sectional study. Physiotherapy, 2019; 105(3)10.1016/j.physio.2018.11.006

440 NHS England, Health literacy 'how to' guide, 2020. (last accessed 6 January 2026)

441 Scottish Government, Making it Easier - a health literacy action plan, 2017. (last accessed 6 January 2026)

442 Truong, M., & Fenton, S., Understanding the Current Landscape of Health Literacy Interventions within Health Systems. Perspectives in Health Information Management, 2022; 15(19)PMID: 35692852 PMCID: PMC9123532

443 NHS Education Scotland and Scottish Government, Scottish Psychological Trauma Training Plan, 2019. (last accessed 6 January 2026)

444 Substance Abuse and Mental Health Services Administration. SAMHSA’s Concept of Trauma and Guidance for a Trauma-Informed Approach, 2014, HHS Publication No. (SMA) 14-4884. RockVille, MD, USA: Substance Abuse and Mental Health Services Administration

445 Gopal, D. P., Hunter, M., Butler, D., et al., Trauma-informed care: what does it mean for general practice? British Journal of General Practice, 2023; 73(730), 229. 10.3399/bjgp23x732837

446 Purkey, E., Patel, R., and Phillips, S. P., Trauma-informed care: Better care for everyone. Canadian Family Physician, 2018; 64(3), 170–172. URL: (last accessed 6 January 2026)

447 Karran, E. L., Cashin, A. G., Barker, T., et al., The ‘what’ and ‘how’ of screening for social needs in healthcare settings: a scoping review. PeerJ, 2023; 11, e15263. 10.7717/peerj.15263

448 Brcic, V., Eberdt, C., and Kaczorowski, J., Development of a Tool to Identify Poverty in a Family Practice Setting: A Pilot Study. International Journal of Family Medicine, 2011, 812182–7. 10.1155/2011/812182

449 Public Health Scotland, Financial Inclusion referral Pathways, 2024. (last accessed 6 January 2026)

450 Improvement Service, Welfare Advice and Health Partnerships, 2024. (last accessed 6 January 2026)

451 Healthcare Improvement Scotland, The Quality Framework for Community Engagement and Participation, 2023. (last accessed 6 January 2026)